Sports lead the volume. Where do event contracts go next? Beyond sports, with session partner @Wedbush @HadickM (@dragonfly), @Cboe's JJ Kinahan, Cantor Fitzgerald's Matthew DeCicco and CoinFund's Einar Braathen Thu Oct 22, Main Stage, NYC

Medicare Open Enrollment closes December 7. Auto-renewal is the default — but plans change every year. Here's what to review before the window closes. wedbush.com/open-enrollment-… 🗓️ #Wedbush #Medicare #OpenEnrollment #FinancialFocus

Alzheimer's disease affects ~7M Americans, and while approved treatments exist, uptake remains limited by IV infusions and safety concerns. Equity Research Analyst, Laura Chico, Ph.D. initiates on Korsana Biosciences ($KRSA) at #OUTPERFORM ($44 PT), developing a next-gen therapy designed to clear amyloid plaques more deeply and conveniently, with initial data expected mid-2027. #EquityResearch #Biotech #Alzheimers #Neuroscience #Investing

A new asset class has entered the market. 🏒 Wedbush is proud to be among the first firms providing access to CME FSPI Hockey Futures, supporting market participation through its trading, clearing and technology infrastructure. Read the full release here: wedbush.com/wedbush-expands-… #FutureSports #CMEGroup #NHL

With $META’s Muse launch this week and its growing product lineup, Ygal Arounian, MD, Equity Research, thinks this is just the beginning of the company’s next chapter. He spoke about this and more with @MorganLBrennan on @CNBCMorningCall. cnbc.com/video/2026/09/24/yg…

With rising demand for cyber defense and risk solutions, Steven Wahrhaftig, VP, Equity Research, joined @rogerfpetersen on @BNNBloomberg for a look at Steven’s top picks within the space. $CRWD $RBRK $PANW Watch here: bnnbloomberg.ca/video/shows/…

Food should not hurt. 🍽️ Martin Fan, Ph.D. initiates on Eupraxia ($EPRX) at #OUTPERFORM ($17 PT). EoE, the most frequent cause of food getting stuck in the esophagus, affects 1 in 700 people. Martin sees it as the next big GI indication after IBD. $EPRX is making a proven short-term treatment available long-term. $EPRX joins Martin's growing EoE coverage alongside emerging names $ACRS and $TRAX. #EquityResearch #Biotech #EoE #GastroIntestinal #Investing

🎥: Steven Wahrhaftig, VP, Equity Research, joined @YahooFinance’s @ines_ferre to discuss the cybersecurity companies best positioned for the AI era, the growing need for AI guardrails, and key trends shaping the sector. $CRWD $PANW $TENB $DDOG #Cybersecurity #AI finance.yahoo.com/video/cybe…

🛡️Equity Research Analyst, Steven Wahrhaftig is assuming coverage of the cybersecurity sector. His central thesis: AI isn't growing the cyber budget, it's redistributing it. Steven’s top #OUTPERFORM picks: @PaloAltoNtwks (PANW), @rubrikInc (RBRK), @CrowdStrike (CRWD), and @datadoghq (DDOG). #EquityResearch #Cybersecurity #AI #Investing

The biggest changes to family tax benefits in decades took effect in 2026. There are five months left to make sure you're taking full advantage. Here's the checklist. wedbush.com/child-related-ta…👨‍👩‍👧‍👦 #Wedbush #TaxCredits #FamilyFinance #FinancialFocus

Equity Research Analyst, David Nierengarten, Ph.D. initiated on Aktis Oncology ($AKTS) at #OUTPERFORM ($35 PT). AKTS is developing targeted cancer therapies that deliver a radioactive payload directly to tumor cells, killing them from within while sparing healthy tissue. Two programs are in the clinic with data expected starting in 1Q27. #EquityResearch #Biotech #Oncology #Radiopharmaceuticals #Investing